Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

rrworm Jun. 17 at 2:54 AM

$NKTR think this might be new 255 data https://congress-distribution.ehaweb.org/from.storage?image=RZshABASE-rg9u-zI63Z1FKGEkkA5btVY0ClFWMakFiEF2ghkJ3_kG6CZRWyT9pX0

1 · Reply

toInfinit3 Jun. 16 at 8:05 PM

$NKTR $GASS.X a good choice for you

0 · Reply

fantastex Jun. 16 at 7:51 PM

$NKTR I saw a similar pattern with $CHWY long time ago when it was trading around 12. Hopefully this will be the same. Fingers crossed fellas 🤞🏻

0 · Reply

topstockalerts Jun. 16 at 7:22 PM

$NKTR not bad today.. 💰🍾🚨

0 · Reply

Yimmied2 Jun. 16 at 6:55 PM

$NKTR

0 · Reply

Bulltrader988 Jun. 16 at 6:55 PM

$NKTR as always: someone knows something? 👃👀

0 · Reply

Bulltrader988 Jun. 16 at 6:21 PM

$NKTR sniffing something here 👃👀

0 · Reply

breakoutstock Jun. 16 at 4:56 PM

$NKTR my prediction is good data. $LLY comes to the table and buys the company. It’s a no brainer.

4 · Reply

Patrick2343 Jun. 16 at 3:34 PM

$NKTR Shorts are having a field day. Bot this data better be good.

0 · Reply

WiseGuyInvestin Jun. 16 at 12:29 PM

$NKTR either this week or next it will be rocket time 🚀🚀

1 · Reply

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Jun 10, 2025, 5:26 PM EDT - 6 days ago

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

May 13, 2025, 5:00 PM EDT - 4 weeks ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 10:08 PM EDT - 5 weeks ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 5 weeks ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 6:00 PM EDT - 6 weeks ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Mar 20, 2025, 6:00 PM EDT - 3 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 3 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 3 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 3 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 3 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 4 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 4 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 4 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 5 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

Dec 7, 2024, 12:00 PM EST - 6 months ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nov 18, 2024, 3:30 PM EST - 7 months ago

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nov 14, 2024, 9:11 AM EST - 7 months ago

Multiple Catalysts Ahead For Nektar Therapeutics

Nov 8, 2024, 12:21 AM EST - 7 months ago

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:15 PM EST - 7 months ago

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 10:15 AM EST - 7 months ago

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 6:00 PM EST - 7 months ago

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nov 4, 2024, 1:44 PM EST - 8 months ago

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Nov 4, 2024, 8:30 AM EST - 8 months ago

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Oct 31, 2024, 6:00 PM EDT - 8 months ago

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Oct 29, 2024, 9:00 AM EDT - 8 months ago

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Oct 17, 2024, 12:07 PM EDT - 8 months ago

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Sep 25, 2024, 3:30 AM EDT - 9 months ago

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Sep 3, 2024, 9:00 AM EDT - 10 months ago

Nektar Management to Present at Upcoming Investor Conferences

Aug 10, 2024, 9:04 AM EDT - 11 months ago

Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:15 PM EDT - 11 months ago

Nektar Therapeutics Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 6:00 PM EDT - 11 months ago

Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets

Jun 12, 2024, 9:30 AM EDT - 1 year ago

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

May 9, 2024, 10:40 PM EDT - 1 year ago

Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Reports First Quarter 2024 Financial Results

May 2, 2024, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

Mar 22, 2024, 2:00 PM EDT - 1 year ago

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 5, 2024, 9:00 AM EST - 1 year ago

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Mar 4, 2024, 10:54 PM EST - 1 year ago

Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 4:15 PM EST - 1 year ago

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

Mar 4, 2024, 8:30 AM EST - 1 year ago

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

Feb 27, 2024, 6:00 PM EST - 1 year ago

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 6:00 PM EST - 1 year ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

Jan 3, 2024, 6:00 PM EST - 1 year ago

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Dec 11, 2023, 6:00 PM EST - 1 year ago

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 7, 2023, 9:11 PM EST - 1 year ago

Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:15 PM EST - 1 year ago

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

Oct 13, 2023, 8:30 AM EDT - 1 year ago

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

rrworm Jun. 17 at 2:54 AM

$NKTR think this might be new 255 data https://congress-distribution.ehaweb.org/from.storage?image=RZshABASE-rg9u-zI63Z1FKGEkkA5btVY0ClFWMakFiEF2ghkJ3_kG6CZRWyT9pX0

1 · Reply

toInfinit3 Jun. 16 at 8:05 PM

$NKTR $GASS.X a good choice for you

0 · Reply

fantastex Jun. 16 at 7:51 PM

$NKTR I saw a similar pattern with $CHWY long time ago when it was trading around 12. Hopefully this will be the same. Fingers crossed fellas 🤞🏻

0 · Reply

topstockalerts Jun. 16 at 7:22 PM

$NKTR not bad today.. 💰🍾🚨

0 · Reply

Yimmied2 Jun. 16 at 6:55 PM

$NKTR

0 · Reply

Bulltrader988 Jun. 16 at 6:55 PM

$NKTR as always: someone knows something? 👃👀

0 · Reply

Bulltrader988 Jun. 16 at 6:21 PM

$NKTR sniffing something here 👃👀

0 · Reply

breakoutstock Jun. 16 at 4:56 PM

$NKTR my prediction is good data. $LLY comes to the table and buys the company. It’s a no brainer.

4 · Reply

Patrick2343 Jun. 16 at 3:34 PM

$NKTR Shorts are having a field day. Bot this data better be good.

0 · Reply

WiseGuyInvestin Jun. 16 at 12:29 PM

$NKTR either this week or next it will be rocket time 🚀🚀

1 · Reply

Hastein Jun. 16 at 11:21 AM

$NKTR I look forward to good clinical results and good lawsuit results Dispositive motion file

1 · Reply

Newbilly Jun. 16 at 2:39 AM

$NKTR This is our week. Feeling it !!

0 · Reply

Bulltrader988 Jun. 15 at 12:01 PM

$NKTR positive data and this moves fast... 👃👀

2 · Reply

BK217 Jun. 14 at 1:44 PM

$NKTR when they fuck up P2b my main man breakout and I are getting these sick shirts to commemorate the event

3 · Reply

BiotechBlues Jun. 14 at 4:11 AM

$NKTR stolen shamelessly from seedy19tron on twitter. These are '$NKTR scenarios' by Jeffries Bank and do not reflect my opinions or his lol

0 · Reply

bshokeen Jun. 13 at 9:22 PM

$NKTR New major risk - Share price stability

0 · Reply

breakoutstock Jun. 13 at 6:07 PM

$NKTR Jeffries is putting a $120 target price of good strong data. Been saying this for a while. And (my opinion) another 10x if this thing goes to market. 🚀

1 · Reply

Don_Frye Jun. 13 at 3:21 PM

$NKTR volume sa

0 · Reply

Bug1 Jun. 13 at 1:50 PM

$NKTR another one... it seems they multiply by the dozen! Can u share pacer historical performance... that would be interesting!

0 · Reply

BK217 Jun. 13 at 1:05 PM

$NKTR the latest trial docs do not paint a good picture for Nektar, either for its success in the trial itself, or more broadly for the success of Rezpeg Further, Lilly makes some pretty good claims about how it was the one actually damaged by Nektar’s defamation Now wouldn’t THAT be something..! @breakoutstock

6 · Reply

Batweevil Jun. 12 at 7:50 PM

$NKTR the absolute worst thing ive bought in a while. Got stopped out at 9.25 got back in at 9.15 and just more bleeding.

1 · Reply

fantastex Jun. 12 at 7:45 PM

$NKTR woah they killed this.

0 · Reply

Market Cap	106.63M
Revenue (ttm)	98.43M
Net Income (ttm)	-118.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-120.86%
Debt to Equity Ratio	0.00

Volume	884,800
Avg Vol	222,800
Day's Range	N/A - N/A
Shares Out	12.41M
Stochastic %K	34%
Beta	0.55
Analysts	Strong Sell
Price Target	$73.71